Ann Intern Med 8 Jan 2007

A systematic review attempts to look at all studies which compare generalist with specialist care. This is doomed for various reasons discussed in the accompanying editorial, not least because most of the studies are observational, very few are randomised, it is generally impossible to adjust for case-mix, and it is very difficult to assess publication […]

Read More…

Lancet 6 Jan 2007

This study shows that when given early after adjuvant chemotherapy for HER-2 positive breast cancer, trastuzumab provides significant mortality benefit in as little as two years. But the Herceptin debate is certainly not over – the benefit is small, the cardiac dangers great, the long-term effects unknown, the dosage uncertain and the costs enormous – […]

Read More…